Announcements Trials
Browse Landscape

Phase

Phase 1 6

Status

Completed 6

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 13Other hematologic neoplasm 12Other solid neoplasm 6Myeloid 6Thoracic 1Dermatologic 1

Conditions

Solid Tumors 4Solid Tumor 1Lymphoid Malignancy 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × navitoclax × Other solid neoplasm × Clear all
NCT00878449 2018-06-06

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

AbbVie

Phase 1 Completed
12 enrolled
Other solid neoplasm

Solid Tumors

NCT00887757 2017-11-21

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
46 enrolled
Other solid neoplasm

Solid Tumors

NCT00891605 2017-11-21

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
19 enrolled
Other solid neoplasm

Solid Tumors

NCT00982566 2017-11-21

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

AbbVie

Phase 1 Completed
37 enrolled
Other solid neoplasm

Lymphoid Malignancy

NCT01009073 2017-11-20

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

AbbVie

Phase 1 Completed
51 enrolled
Other solid neoplasm

Solid Tumors

NCT00888108 2012-05-22

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

Abbott

Phase 1 Completed
41 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡